Allosteric mechanism of cyclopropylindolobenzazepine inhibitors for HCV NS5B RdRp via dynamic correlation network analysis.

HCV RNA dependent RNA polymerase (RdRp) nonstructural protein 5B (NS5B) is a major target against hepatitis C virus (HCV) for antiviral therapy. Recently discovered cyclopropylindolobenzazepine derivatives have been considered as the most potent for their ability to bind the thumb site 1 domain and allosterically inhibit HCV NS5B RdRp activity. However, the allosteric mechanism for these derivatives has not been clarified at the molecular level. In this study, fluctuation correlation networks were constructed based on all-atom molecular dynamics simulations to elucidate the allosteric mechanism. The fluctuation correlation networks between free and M2 bound NS5B are significantly different. Information can better transfer from the allosteric site to the catalytic site for bound NS5B than for free NS5B. Thus, the hypothesis of "binding induced allosteric regulation" is proposed to link the enzyme activation and inhibitor binding and then confirmed by the mutant network. Finally, one possible allosteric pathway was identified with the shortest path and evaluated by the perturbation of the network. These methods will be helpful to identify the allosteric pathway of other proteins and to design new drugs targeting the pathway.

[1]  Hao Liu,et al.  Synergistic Allosteric Mechanism of Fructose-1, 6-bisphosphate and Serine for Pyruvate Kinase M2 via Dynamics Fluctuation Network Analysis , 2016, J. Chem. Inf. Model..

[2]  N. Meanwell,et al.  Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase , 2014, Antimicrobial Agents and Chemotherapy.

[3]  Ray Luo,et al.  Synergistic Modification Induced Specific Recognition between Histone and TRIM24 via Fluctuation Correlation Network Analysis , 2016, Scientific Reports.

[4]  J. Lemm,et al.  Potency and Resistance Analysis of Hepatitis C Virus NS5B Polymerase Inhibitor BMS-791325 on All Major Genotypes , 2014, Antimicrobial Agents and Chemotherapy.

[5]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[6]  Jian Zhang,et al.  Induced fit or conformational selection for RNA/U1A folding. , 2010, RNA.

[7]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[8]  S. Harper,et al.  Mechanismof Action and Antiviral Activity of Benzimidazole-Based AllostericInhibitors of the Hepatitis C Virus RNA-Dependent RNAPolymerase , 2003, Journal of Virology.

[9]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[10]  Hai-Feng Chen,et al.  Mechanism of Coupled Folding and Binding in the siRNA-PAZ Complex. , 2008, Journal of chemical theory and computation.

[11]  Stephen J. Garland,et al.  Algorithm 97: Shortest path , 1962, Commun. ACM.

[12]  C. Stedman,et al.  Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. , 2013, The New England journal of medicine.

[13]  F. Rey,et al.  Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides , 2002, Journal of Virology.

[14]  M E J Newman,et al.  Community structure in social and biological networks , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Brittny C. Davis,et al.  Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase , 2013, Proteins.

[16]  James T. Simpson,et al.  445 A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION , 2011 .

[17]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[18]  Kenneth A. Johnson,et al.  Assembly, Purification, and Pre-steady-state Kinetic Analysis of Active RNA-dependent RNA Polymerase Elongation Complex* , 2012, The Journal of Biological Chemistry.

[19]  Wei Wang,et al.  Characterization of domain-peptide interaction interface: prediction of SH3 domain-mediated protein-protein interaction network in yeast by generic structure-based models. , 2012, Journal of proteome research.

[20]  Riccardo Baron,et al.  LSD1/CoREST is an allosteric nanoscale clamp regulated by H3-histone-tail molecular recognition , 2012, Proceedings of the National Academy of Sciences.

[21]  D. Beveridge,et al.  Free energy via molecular simulation: applications to chemical and biomolecular systems. , 1989, Annual review of biophysics and biophysical chemistry.

[22]  C. Trautwein,et al.  Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. , 2012, Journal of hepatology.

[23]  Chong-Hwan Chang,et al.  Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. , 2014, Journal of medicinal chemistry.

[24]  Youyong Li,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models. , 2013, The journal of physical chemistry. B.

[25]  Ray Luo,et al.  Binding induced folding in p53-MDM2 complex. , 2007, Journal of the American Chemical Society.

[26]  M. Otto,et al.  Structure of Hepatitis C Virus Polymerase in Complex with Primer-Template RNA , 2012, Journal of Virology.

[27]  B. Beno,et al.  Mechanism of Inhibition for BMS-791325, a Novel Non-nucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase , 2014, The Journal of Biological Chemistry.

[28]  C. Cooper,et al.  31 SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS , 2010 .

[29]  P. Marcellin,et al.  Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. , 2014, Gastroenterology.

[30]  Rafael Rodríguez-Puente,et al.  Algorithm for shortest path search in Geographic Information Systems by using reduced graphs , 2013, SpringerPlus.

[31]  Ray Luo,et al.  New Force Field on Modeling Intrinsically Disordered Proteins , 2014, Chemical biology & drug design.

[32]  Uwe Koch,et al.  Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site* , 2005, Journal of Biological Chemistry.

[33]  P. Tebas,et al.  Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection , 2014, Antimicrobial Agents and Chemotherapy.

[34]  P. Simister,et al.  A Comprehensive Structure-Function Comparison of Hepatitis C Virus Strain JFH1 and J6 Polymerases Reveals a Key Residue Stimulating Replication in Cell Culture across Genotypes , 2011, Journal of Virology.

[35]  Tingjun Hou,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. , 2014, Physical chemistry chemical physics : PCCP.

[36]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[37]  I. Jacobson,et al.  2005 VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS , 2010 .

[38]  Youyong Li,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. , 2014, Physical chemistry chemical physics : PCCP.

[39]  R. Nussinov,et al.  Unraveling structural mechanisms of allosteric drug action. , 2014, Trends in pharmacological sciences.

[40]  Blake R. Peterson,et al.  Structural Insights into Mechanisms of Catalysis and Inhibition in Norwalk Virus Polymerase* , 2008, Journal of Biological Chemistry.

[41]  David E Draper,et al.  Electrostatic interactions in a peptide--RNA complex. , 2003, Journal of molecular biology.

[42]  M. Yi,et al.  Mutagenesis Analysis of the rGTP-Specific Binding Site of Hepatitis C Virus RNA-Dependent RNA Polymerase , 2005, Journal of Virology.

[43]  W. C. Still,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999 .

[44]  T. Hassanein,et al.  2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS , 2010 .

[45]  Ray Luo,et al.  Recognition mechanism between Lac repressor and DNA with correlation network analysis. , 2015, The journal of physical chemistry. B.

[46]  B. Beno,et al.  Ligand-induced changes in hepatitis C virus NS5B polymerase structure. , 2010, Antiviral research.

[47]  Vladimir D. Axelrod,et al.  Modulation of Hepatitis C Virus RNA-dependent RNA Polymerase Activity by Structure-based Site-directed Mutagenesis* , 2002, The Journal of Biological Chemistry.

[48]  B. Zagrovic,et al.  Conformational selection and induced fit mechanism underlie specificity in noncovalent interactions with ubiquitin , 2009, Proceedings of the National Academy of Sciences.

[49]  Ray Luo,et al.  Kink turn sRNA folding upon L7Ae binding using molecular dynamics simulations. , 2013, Physical chemistry chemical physics : PCCP.

[50]  D. Lamarre,et al.  Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate. , 2004, Nucleic acids research.